Methadone Withdrawal: Timeline, Symptoms & Recovery

Methadone withdrawal is the cluster of physical and psychological symptoms that emerge when mu-opioid receptor activity drops sharply after stopping one of the most long-acting synthetic opioids prescribed for opioid use disorder.

Because methadone clears from the body far more slowly than short-acting opioids, withdrawal arrives later and lasts substantially longer than most people expect.

Stopping methadone cold turkey dramatically amplifies this process and is never medically safe.

Understanding the timeline, what drives methadone withdrawals, and how evidence-based treatment makes coming off methadone safely possible is what separates a dangerous attempt from a successful recovery.

Key Takeaways

• According to MedlinePlus (NIH), methadone withdrawal symptoms begin within 30 hours of the last dose and can persist up to 10 days in the acute phase, with some symptoms continuing for weeks to months during post-acute withdrawal syndrome.
• Methadone has a half-life ranging from 8 to 59 hours with a mean of approximately 24 hours (Eap et al., 2002), making methadone withdrawals significantly more protracted than withdrawal from heroin or short-acting prescription opioids.
• Research published in Basic and Clinical Pharmacology and Toxicology (Chalabianloo et al., 2024) confirmed that CYP2B6 genetic polymorphisms are the primary determinant of methadone metabolism, meaning individual withdrawal severity and duration vary substantially based on genetics.
• According to SAMHSA, approximately 74% of individuals receiving methadone stayed in opioid use disorder treatment compared to 46% of those receiving buprenorphine, underscoring the clinical value of sustained treatment engagement over short-term withdrawal management alone.
• The Clinical Opioid Withdrawal Scale (COWS) requires a score above 8 and a minimum 5-day waiting period after the last methadone dose before buprenorphine induction can safely proceed without triggering precipitated withdrawal.

What Is Methadone Withdrawal?

Methadone withdrawal is the neurobiological rebound produced when a full mu-opioid receptor agonist with a long, variable half-life is removed from a nervous system that has adapted to require its presence for baseline physiological function.

Methadone and Physical Dependence

Methadone produces physical dependence by chronically suppressing the brain’s noradrenergic stress response through sustained mu-opioid receptor occupancy, driving compensatory neuroadaptations that leave the nervous system hyperexcitable when the drug is removed.

Key pharmacological facts that determine methadone withdrawal severity:

• Full mu-opioid receptor agonist profile: methadone binds and activates mu-opioid receptors with full efficacy, producing the complete opioid effect including analgesia, euphoria, sedation, and respiratory depression; physical dependence develops at any dose used consistently over time
• NMDA receptor antagonism: methadone simultaneously blocks NMDA glutamate receptors through a mechanism shared with ketamine, adding a glutamatergic excitatory rebound component to cessation that amplifies restlessness and dysphoria specifically during methadone withdrawal
• CYP2B6 as primary metabolic determinant: CYP2B6 genetic polymorphisms govern how quickly methadone is metabolized and cleared; slow CYP2B6 metabolizers accumulate higher plasma concentrations and experience later withdrawal onset and longer duration than rapid metabolizers
• R-enantiomer activity: methadone is prescribed as a racemic mixture; the R-enantiomer carries almost all opioid receptor activity, while the S-enantiomer contributes to cardiac QTc prolongation, a separate clinical risk that requires ECG monitoring during maintenance and withdrawal

Physical dependence develops in patients on methadone maintenance therapy (MMT) and in individuals who have misused methadone recreationally, as the underlying neuroadaptation is identical regardless of the clinical context.

Methadone vs. Other Opioid Withdrawals

Methadone withdrawal is more delayed in onset and substantially more protracted than withdrawal from shorter-acting opioids, even though the underlying mechanism of locus coeruleus rebound is shared across all opioid classes.

The extended duration of methadone withdrawals catches most individuals off guard. Physical symptoms peak later, persist longer, and require sustained clinical management well beyond what short-acting opioid detox requires.

Why Stopping Methadone Triggers Withdrawal

Stopping methadone triggers withdrawal because the locus coeruleus, the brain’s primary noradrenergic nucleus, undergoes hyperactivation when the chronic mu-opioid receptor suppression maintaining its equilibrium is suddenly removed.

The Locus Coeruleus Rebound Mechanism

Chronic methadone use suppresses locus coeruleus firing by binding mu-opioid receptors on noradrenergic neurons, and the nervous system compensates by upregulating adrenergic receptor sensitivity to maintain functional output under persistent opioid inhibition.

The neurobiological sequence driving methadone withdrawals:

• Chronic suppression: sustained methadone exposure reduces locus coeruleus activity; the nervous system responds by increasing adrenergic receptor density and sensitivity across downstream systems to maintain physiological balance
• Clearance: CYP2B6 enzymes metabolize methadone over 24 to 36 hours after the last dose; mu-opioid receptor occupancy falls below the threshold required to maintain locus coeruleus inhibition
• Noradrenergic storm: the disinhibited locus coeruleus releases excessive norepinephrine throughout the brain and peripheral nervous system, producing tachycardia, sweating, hypertension, piloerection, severe anxiety, and muscle pain simultaneously
• NMDA rebound: cessation of methadone’s NMDA receptor antagonism adds a glutamatergic excitatory component not seen with most shorter-acting opioids, intensifying restlessness and dysphoria specific to detoxing off methadone

Understanding the full scope of opioid use disorder clarifies why these neurobiological adaptations require medical management rather than willpower-based self-detox attempts.

Why Stopping Methadone Cold Turkey Is Medically Dangerous

Stopping methadone cold turkey eliminates the graduated receptor adjustment that medical tapering provides, triggering all components of the withdrawal syndrome simultaneously at maximum intensity.

Clinical dangers of abrupt methadone cessation:

• Aspiration pneumonia: uncontrolled vomiting during severe withdrawal without medical supervision carries documented risk of fatal aspiration pneumonia, particularly in individuals with impaired airway protective reflexes
• Cardiac arrhythmia from electrolyte depletion: combined sweating, vomiting, and diarrhea rapidly deplete potassium, sodium, and magnesium; the resulting electrolyte imbalance produces life-threatening cardiac arrhythmia independent of the opioid withdrawal mechanism itself
• Overdose after cessation: methadone tolerance drops rapidly once the drug clears; individuals who relapse following cold turkey cessation regularly overdose at their pre-cessation dose because their mu-opioid receptor tolerance no longer accommodates it
• Psychiatric crisis: the anhedonia, severe anxiety, and depression of peak methadone withdrawal precipitate suicidal ideation in individuals with co-occurring major depressive disorder or borderline personality disorder, requiring emergency clinical intervention

Individuals with recognized co-occurring mental health conditions face amplified psychiatric risk from unmanaged methadone cessation and require integrated dual diagnosis support throughout the withdrawal process.

Rediscover Life at Olympic Behavioral Health

Get the compassionate support you deserve. We're here to help you reclaim joy, wellness, and a brighter future.

Our Facility

Methadone Withdrawal Timeline

Methadone withdrawal follows four distinct phases driven by the drug’s long and variable half-life, with symptom onset delayed by 24 to 36 hours but duration and intensity substantially exceeding those of shorter-acting opioid withdrawals.

Phase 1 (Hours 0 to 24): Pre-Onset

During the first 24 hours after the last methadone dose, plasma concentrations are declining but mu-opioid receptor occupancy remains sufficient to prevent full withdrawal emergence in most individuals.

What happens during hours 0 to 24:

• Methadone plasma concentrations decline gradually as CYP2B6 enzymes metabolize the drug, but the long half-life delays the drop in receptor occupancy below the withdrawal threshold for most individuals
• Mild early signs may appear in rapid CYP2B6 metabolizers: slight restlessness, increased yawning, mild anxiety, and rhinorrhea as receptor occupancy approaches withdrawal threshold levels
• Slow CYP2B6 metabolizers may experience no symptoms for 36 to 48 hours because higher accumulated plasma concentrations require longer clearance times before receptor vacancy is sufficient to trigger the withdrawal cascade

Phase 2 (Hours 24 to 72): Onset and Escalation

Methadone withdrawal symptoms emerge and escalate between 24 and 72 hours after the last dose as mu-opioid receptor occupancy falls below the threshold required to suppress locus coeruleus firing.

Symptoms appearing and intensifying during onset:

• Profuse sweating, rhinorrhea, lacrimation, and dilated pupils emerge as the first objective COWS-scored signs of active withdrawal; clinicians assess these 3 to 4 times daily in supervised settings to track escalation
• Muscle aches, joint pain, and severe insomnia escalate rapidly as the noradrenergic storm intensifies and methadone’s analgesic coverage is lost from mu-opioid receptors throughout the central nervous system
• Nausea, vomiting, and diarrhea develop as gastrointestinal mu-opioid receptors lose coverage, producing abrupt gut motility restoration that generates abdominal cramping alongside simultaneous vomiting and diarrhea
• COWS scores above 8 indicate clinically significant withdrawal requiring pharmacological intervention; scores above 13 indicate moderate-to-severe withdrawal requiring escalated management

Phase 3 (Days 3 to 10): Peak Withdrawal

Peak methadone withdrawal occurs between days 3 and 7 for most individuals and represents the highest-risk period for relapse, medical complications, and psychiatric crisis in the entire withdrawal trajectory.

The peak phase clinical picture:

• Physical symptoms reach maximum intensity: severe muscle pain, profuse diaphoresis, uncontrolled diarrhea, intractable insomnia, abdominal cramping, tachycardia, and hypertension reach their most debilitating levels simultaneously between days 3 and 7
• Psychological symptoms dominate from days 5 to 10: intense anxiety, severe depression, suicidal ideation, and overwhelming cravings for methadone or other opioids emerge as physical symptoms begin to plateau, creating the sustained dual burden that drives most peak-phase relapse
• CYP2B6 slow metabolizers may not peak until days 5 to 10 due to delayed clearance of higher accumulated plasma concentrations
• The disconnect between gradually improving physical symptoms and persisting psychological distress from days 7 to 10 is the single highest-risk relapse window; patients report feeling psychologically worse even as physical symptoms begin to recede

Phase 4 (Days 10 to 21 and Beyond): Resolution and PAWS

Physical methadone withdrawal symptoms resolve progressively between days 10 and 21, but post-acute withdrawal syndrome (PAWS) extends the clinical recovery window for weeks to months in a significant subset of individuals.

Post-acute resolution and PAWS trajectory:

• Physical resolution: sweating, muscle aches, nausea, and diarrhea subside progressively; insomnia is consistently the last physical symptom to resolve and frequently persists beyond day 21 even after other symptoms have cleared
• PAWS development: persistent anxiety, depression, anhedonia, cognitive impairment, and intermittent cravings emerge weeks to months after acute physical withdrawal resolves, reflecting ongoing neurobiological recalibration of locus coeruleus and dopaminergic reward circuitry
• Anhedonia mechanism: mu-opioid receptor downregulation in the ventral tegmental area and nucleus accumbens reduces dopaminergic reward signaling, making previously rewarding activities feel flat or joyless throughout the PAWS period
• PAWS relapse risk: the emotional blunting and unpredictable craving episodes of PAWS drive relapse weeks after apparent physical recovery, making continued clinical support essential well beyond the 21-day acute withdrawal window

Methadone Withdrawal Symptoms

Methadone withdrawal produces symptoms across physical, autonomic, and psychological domains, reflecting the broad range of neurobiological systems that chronic mu-opioid receptor activation had been regulating.

Common Methadone Withdrawal Symptoms

Common methadone withdrawal symptoms appear consistently during onset and escalation across Clinical Opioid Withdrawal Scale assessments, peer-reviewed clinical research, and opioid treatment program documentation.

Common symptoms appearing in the first 24 to 72 hours:

• Profuse sweating and temperature dysregulation: locus coeruleus disinhibition disrupts hypothalamic thermoregulation, producing drenching sweats alternating with chills throughout the acute withdrawal phase
• Rhinorrhea, lacrimation, and yawning: noradrenergic hyperactivation stimulates secretory glands throughout the face and upper respiratory tract, producing the objective signs that COWS scores as evidence of active opioid withdrawal
• Muscle aches and joint pain: methadone’s analgesic coverage disappears as mu-opioid receptors lose occupancy, unmasking both opioid-induced hyperalgesia and previously suppressed pain that generates severe musculoskeletal pain disproportionate to any physical tissue damage
• Nausea, vomiting, and diarrhea: gastrointestinal mu-opioid receptor disinhibition restores rapid gut motility, and the combined output of nausea, vomiting, and diarrhea creates severe dehydration risk within the first 48 to 72 hours of withdrawal
• Insomnia and restlessness: noradrenergic rebound produces central nervous system hyperarousal that prevents sleep despite profound physical exhaustion; restless leg syndrome compounds the insomnia throughout the acute phase

Severe Methadone Withdrawal Symptoms

Severe methadone withdrawal symptoms emerge during peak phase and represent the presentations most likely to produce medical emergencies or drive relapse without clinical intervention.

Seek immediate emergency medical care if any of the following occur:

1. Uncontrolled vomiting with inability to retain fluids for more than 12 hours, risk of severe dehydration, electrolyte imbalance, and aspiration pneumonia
2. Chest pain, irregular heartbeat, or resting heart rate above 120 bpm, electrolyte-mediated cardiac arrhythmia requires emergency evaluation
3. Suicidal ideation or active intent, opioid withdrawal-associated depression can reach clinical crisis threshold during peak phase
4. High fever above 103°F (39.4°C), signals secondary infection or metabolic crisis, not standard withdrawal
5. Seizures are rare but documented in individuals with co-occurring benzodiazepine dependence or severe metabolic disturbance

Additional severe presentations requiring supervised clinical management:

• Severe hypertension exceeding 180/110 mmHg requires urgent alpha-2 adrenergic receptor agonist treatment, as sustained hypertension during peak withdrawal carries cerebrovascular risk that cannot be managed without pharmacological intervention
• Severe dehydration producing decreased urination, altered mental status, or skin tenting requires intravenous fluid and electrolyte repletion that oral hydration cannot accomplish in a home setting

Long-Term Methadone Withdrawal Symptoms

Long-term methadone withdrawal symptoms reflect the sustained neurobiological recalibration required after years of mu-opioid receptor adaptation.

Long-term and post-acute withdrawal symptoms:

• Anhedonia and emotional blunting: dopaminergic reward circuitry normalization in the nucleus accumbens takes weeks to months; previously rewarding activities feel flat or joyless, significantly increasing relapse risk in the absence of behavioral treatment targeting this phase
• Persistent anxiety and depression meeting DSM-5 criteria: noradrenergic and serotonergic system normalization is gradual; residual anxiety frequently meets diagnostic criteria for generalized anxiety disorder and responds to clinical treatment rather than spontaneous resolution
• Cognitive impairment: working memory deficits, slowed processing speed, and disrupted executive function persist for weeks, driven by ongoing prefrontal cortex dopaminergic recalibration following long-term opioid suppression
• Cue-triggered cravings: conditioned cue reactivity to people, places, and objects associated with methadone use persists well beyond physical withdrawal, representing the primary behavioral mechanism driving PAWS-period relapse without continued clinical intervention

Individuals experiencing persistent post-acute symptoms alongside recognized signs of substance addiction should pursue integrated dual diagnosis evaluation rather than waiting for symptoms to resolve without clinical support.

Methadone Withdrawal Treatment and Recovery

Evidence-based methadone withdrawal treatment targets the locus coeruleus hyperactivation driving acute symptoms, uses medically supervised tapering to eliminate the risks of abrupt cessation, and extends recovery support through the post-acute withdrawal period.

Medical Detox and Supervised Tapering

Medically supervised detox through a licensed opioid treatment program (OTP) or addiction medicine specialist is the safest and most clinically effective approach to detoxing off methadone.

Components of a supervised methadone detox:

• Individualized taper schedule: dose reductions of 5 to 10 mg per week allow locus coeruleus and noradrenergic systems to recalibrate incrementally, reducing peak COWS scores and preventing the noradrenergic storm of abrupt cessation
• COWS monitoring 3 to 4 times daily: clinical teams score objective and subjective withdrawal severity in real time and adjust pharmacological interventions based on COWS data rather than subjective patient report alone
• Lofexidine (Lucemyra): the first FDA-approved non-opioid medication specifically for opioid withdrawal symptom management; lofexidine directly suppresses locus coeruleus hyperactivation through alpha-2 adrenergic receptor agonism, reducing sweating, tachycardia, anxiety, and muscle aches without opioid receptor activity or abuse potential
• Clonidine: an older alpha-2 adrenergic receptor agonist used off-label for withdrawal autonomic symptom management; effective for hypertension, sweating, and rhinorrhea but does not reduce drug cravings and requires blood pressure monitoring due to hypotension risk

Buprenorphine Induction After Methadone

Buprenorphine (Suboxone) provides an evidence-based pathway for transitioning from methadone to a maintenance medication with a lower overdose risk profile, but requires precise clinical timing to avoid precipitated withdrawal.

Critical clinical requirements for buprenorphine after methadone:

• Precipitated withdrawal risk: buprenorphine’s high mu-opioid receptor affinity displaces methadone from receptors if administered too early, triggering sudden severe withdrawal that cannot be reversed with additional opioids and is substantially more intense than standard withdrawal
• Minimum waiting period: clinical guidelines require a minimum of 5 days from the last methadone dose and a COWS score above 8 confirming sufficient receptor vacancy before the first buprenorphine dose is administered
• Low-dose induction protocol: buprenorphine induction after methadone begins at 2 mg with gradual upward titration over multiple days rather than the more rapid inductions used for short-acting opioids, minimizing residual-methadone-precipitated withdrawal risk

Rediscover Life at Olympic Behavioral Health

Get the compassionate support you deserve. We're here to help you reclaim joy, wellness, and a brighter future.

Our Facility

FDA-Approved MAT for Long-Term Recovery

Medication-assisted treatment with FDA-approved opioid agonist or antagonist therapy substantially improves long-term outcomes for opioid use disorder and is clinically superior to detox-only approaches for most individuals with established methadone dependence.

FDA-approved MAT options following methadone withdrawal:

• Buprenorphine/naloxone (Suboxone): partial agonist maintenance with a ceiling effect on respiratory depression that makes it substantially safer for outpatient prescription than full agonist therapy; requires the minimum 5-day post-methadone waiting period before induction
• Naltrexone (Vivitrol): a full mu-opioid receptor antagonist available as a monthly injection that blocks all opioid effects; appropriate only after full detox completion and verified opioid abstinence, as any residual opioid tolerance at injection time triggers precipitated withdrawal
• Continued methadone maintenance: for many individuals, continuing methadone at a stabilizing dose through a licensed OTP provides better long-term outcomes than repeated detox attempts; this clinical decision should be made collaboratively with an addiction medicine specialist

A review of how opioids affect the brain helps individuals and families understand why MAT medications significantly outperform abstinence-only approaches in reducing overdose mortality and sustaining long-term recovery.

Treatment for Methadone Withdrawal at Olympic Behavioral Health

Olympic Behavioral Health provides evidence-based PHP, IOP, and outpatient treatment for individuals in Lantana, Florida recovering from opioid use disorder, including those transitioning from methadone. Olympic does not provide on-site medical detox, patients requiring supervised methadone tapering or acute withdrawal management are referred to a licensed detox facility and then step into Olympic’s structured outpatient continuum.

Partial Hospitalization Program (PHP)

Olympic Behavioral Health’s PHP delivers 6 hours of structured daily clinical programming on weekdays and 3 hours on weekends, providing intensive support for individuals in the post-acute phase of methadone withdrawal who require more clinical structure than standard outpatient care can provide.

PHP treatment components directly relevant to methadone withdrawal recovery:

• CBT groups targeting opioid use disorder: Cognitive behavioral therapy addresses the automatic thought patterns and cue reactivity that drive PAWS-period relapse, building cognitive tools that replace opioid-seeking responses to the emotional distress and craving episodes that characterize post-acute withdrawal
• DBT skills training: Dialectical behavior therapy provides distress tolerance and emotional regulation skills that directly address the anhedonia, anxiety, and emotional blunting that characterize the post-acute withdrawal period following methadone cessation
• Neurofeedback therapy: Olympic Behavioral Health integrates neurofeedback to address the cortical hyperarousal and dysregulated dopaminergic reward circuitry that underlies both ongoing PAWS symptoms and elevated relapse vulnerability during opioid use disorder recovery
• Individual therapy: Minimum weekly 50-minute sessions of individual therapy with a licensed primary therapist address co-occurring anxiety and depressive disorders, trauma, and the shame-based thought patterns that sustain opioid use disorder and complicate recovery from methadone withdrawal

Intensive Outpatient Program (IOP)

Olympic Behavioral Health’s IOP operates Monday through Saturday with daily sessions from 9 AM to 12 PM, providing evidence-based opioid use disorder treatment for individuals stepping down from PHP or continuing structured support through the post-acute recovery period while maintaining work, family, or school commitments.

IOP programming supporting long-term methadone withdrawal recovery:

• Relapse prevention programming: structured skill-building targets the emotional states, social contexts, and environmental cues that drive PAWS-period relapse, with individualized strategies for managing the craving episodes that characterize post-acute opioid withdrawal without returning to drug use
• EMDR and rapid trauma resolution: for individuals whose methadone dependence originated in self-medication of PTSD or unresolved trauma, EMDR addresses the underlying driver rather than managing withdrawal symptoms in isolation from their clinical root cause
• Psychoeducation on opioid use disorder: understanding the neurobiological basis of withdrawal, PAWS trajectory, and long-term recovery planning are covered in clinically grounded group sessions, equipping patients to understand their own recovery course and make informed treatment decisions

Dual Diagnosis Psychiatric Evaluation

Olympic Behavioral Health’s board-certified psychiatrist Dr. Nvari and psychiatric ARNP Sabina conduct DSM-5 dual diagnosis evaluations for individuals presenting with opioid use disorder and co-occurring anxiety disorders, major depressive disorder, PTSD, or borderline personality disorder.

Dual diagnosis components directly applicable to methadone withdrawal presentations:

• DSM-5 differential evaluation: distinguishing opioid-induced anxiety and depression from primary mood and anxiety disorders requires the temporal timeline diagnostic approach outlined in DSM-5 guidelines; Olympic Behavioral Health applies this systematically at intake before initiating any psychiatric medication management
• Integrated concurrent treatment: evidence-based guidelines consistently show that treating co-occurring psychiatric disorders and opioid use disorder simultaneously outperforms sequential approaches; Olympic Behavioral Health addresses both concurrently rather than requiring one to resolve before treating the other

Why Structured Outpatient Care Matters After Methadone Withdrawal

The post-acute phase is where recovery is won or lost. Patients completing medical detox are often prepared for the acute 7-to-10-day window but rarely prepared for what follows, weeks of PAWS symptoms, including anhedonia, anxiety, sleep disruption, and intermittent cravings that can feel indistinguishable from relapse. Structured outpatient programming during this phase provides the clinical scaffolding that unstructured recovery cannot.

Olympic Behavioral Health in Lantana, FL (Palm Beach County) provides the structured outpatient continuum that follows medical detox: JCAHO-accredited PHP, IOP, and outpatient programming with integrated dual-diagnosis care, evidence-based behavioral therapies, board-certified psychiatric oversight, trauma assessment for every incoming client, weekly individual therapy, and family support programming including weekly family Zoom meetings.

If you or someone you love is preparing to come off methadone or has already completed detox and needs the next level of structured support call Olympic Behavioral Health at (561) 272-0800 to speak with the admissions team, or verify your insurance online.